Sir, Diabetes mellitus (DM) currently affects more than 62 million Indians. [1] Studies show that approximately 20% of the patients with diabetes have peripheral neuropathy. Evaluation of diabetic neuropathy is important as it has a bearing on the comprehensive management. Conventional evaluation involves testing the sensory, motor and autonomic functions along with deep tendon reflexes. This is a time consuming process. The huge workload in Diabetes Outpatient clinics in India calls for a simple indicator towards the neuropathic process. One of us (S M Katrak) had observed that the loss of hair on the legs, signifying autonomic neuropathy gives a lead to the extent of somatosensory neuropathic deficits. To test this clinical observation, we designed this study. The study was approved by the Institutional Ethics Committee.
Patients with DM reporting paresthesias were included in the study. After obtaining informed valid consent, history was recorded (age, sex, duration of DM, peripheral and autonomic symptoms viz. paresthesias, constipation, urinary complaints, abnormal sweating, and exercise intolerance) and clinical examination was performed (motor system, sensory system viz. fine and crude touch, pain and temperature, vibration and position sense were noted; reflexes and autonomic system viz. resting tachycardia, orthostatic hypotension and the level of hair loss was documented). [2] For the measurement of sensory deficit and hair changes, malleolus was taken as point zero. Toronto Clinical Scoring System (TCSS) was used for grading the severity of neuropathy. [3] In this cohort of 107 patients, mean age was 61.9 years and mean duration of DM was 8.7 years. Twenty four patients had no neuropathy (TCSS score ≤5), 41 had mild neuropathy (TCSS 6-8), 14 had moderate (TCSS 9-11) and 28 patients had severe neuropathy (TCSS ≥12).
Of the 83 patients documented to have neuropathy (TCSS score ≥6), 36 (43%) had a distal stocking hair loss which correlated with the level of pain and temperature loss or the level of impaired fine or crude touch [ Figure 1 ]. Of these 36 patients, 11 had moderate and 25 had severe neuropathy. Thus, 79% patients with moderate and 89% with severe neuropathy had hair loss over the distal part of the legs which corresponded with the level of sensory impairment. None of the patients with mild, pure sensory neuropathy exhibited any hair loss.
Thus the level of hair loss, when present, can be used as a rapid and reliable clinical indicator of moderate to severe diabetic peripheral neuropathy. The somatic components of sensory neuropathy appear to correlate well with this component of autonomic neuropathy (hair loss). The finding of hair loss and its level on the leg (hair loss sign) can serve the clinician well in his busy diabetes clinic. Further, this could potentially be used in follow-up studies of these individuals with diabetes.
The limitations of this study are that patients with mild neuropathy may not exhibit this sign and in female patients who wax their hair, the utility of the sign is lost.
Sir, PPARs are nuclear receptors that promoted fatty acid metabolism. PPAR α agonists (like fibrates) lower triglyceride and increase HDL levels. PPAR γ agonists (like thiazolidinediones) reduce blood glucose. Dual α/γ PPAR/agonist have the dual promise of reducing both blood glucose and triglyerides and increasing HDL. Saroglitazar is the only dural α/γ PPAR/agonist available in India. The drug also holds the distinction of being an 'Indian' drug and is extensively marketed. However, it wasn't the first drug to act on both PPAR receptors -its closely related molecules were tried in the past and were dropped because of cardiac toxicity. Muraglitazar, developed by Bristol Myers Squibb, was the first drug to reach phase III clinical trials in this class. Nissen et al., [1] in an RCT concluded that until and unless the safety of muraglitazar was established in a dedicated CVOT, it should not be approved for clinical use in diabetes based on lab end points alone. Tesaglitazar, another drug in the same class, was found to have renal (reduced glomerular filtration rate) and cardiac adverse effects and Astra zeneca, its developer, pulled the plug on further development, Aleglitazar developed by Roche, also met with the same fate. Several other glitazars (navaglitazar, ragaglitazar, farglitazar, chiglitazar) also went to their early graves. [2] Given the failure of the three drugs in this class, the natural questions that arise are, is this increased MACE a class effect or a molecule specific effect? If we consider it a molecule specific effect, how different is saroglitazar (available in Indian market) from muraglitazar/aloglitazar/ tezaglitazar on a structural level to believe that it will be different? Finally, do we have a reassuring CVOT to allay the fears, given the chequered history of this molecule's ancestors?
These questions do not have easy answers.
CarDiovasCuLar saFety oF Diabetes Drugs
The CVOT is a particularly important safety valve, which FDA built into its approval pathway, ensuring that all anti diabetic drugs have to clear the bar of cardiovascular safety, before they reach the market. Given the cracks in post marketing surveillance, such safety precautions are well founded, even if they come at a higher upfront cost. There is currently no consensus on the duration of CVOTs -since most CVOTs are event driven and take large number of patients. In contrast, the PRESS-VI trial 3 which used saroglitazar has a duration of just 12 weeks with a sample size of 300. The DCGI does not require CVOTs, nor is there is a minimum duration of trial required to ascertain safety. This loophole potentially leaves Indian patients vulnerable to drug-induced adverse effects.
DuaL α/γ ppar/agonists-meChanism oF CarDiaC DysFunCtion
The molecular mechanism of cardiac dysfunction induced by glitazars remained obscure. A recent study in mice treated with tezaglitazar throws light on the mechanism. [3] The action of dual PPAR α/γ agonists requires activation of PPAR γ co-activator-1 (PGC-1). This is a common coactivator for both PPARs and it regulates cardiac fatty acid oxidation, mitochondrial biogenesis and respiration. SIRT1 (sirtuin 1) expression serves as an additional lever of control and regulates PGC-1 expression by acetylation.
A direction reduction in PGC-1, or its deactivation by reduced SIRT1 expression will result in reduction in cardiac mitochondrial number. Glitazars cause competition between PPAR α and γ for PGC-1 and also reduce SIRT1 expression, thereby reducing cardiac mitochondrial abundance. This explains why inspite of being dual agonists, the final effect of glitazars is less than the sum of PPAR α and γ activation.
